February 23, 2024
“The current use of peptides is everything you can think of. From antimicrobial, antioxidant, and anti-obesity uses, to hormone regulation, dyslipidemia, digestion, and cognitive performance enhancement. Virtually every bodily function you can think of utilizes peptides.” – James LaValle, RPh, CCN, MT, DHM, DHPh, A4M Scientific Planning Committee and IPS Steering Committee Chair
The mapping of the human longevity blueprint has launched a new era of research into peptide therapies for precision life extension. Groundbreaking peptide advances welcome a coming age in which the root causes of aging may be targeted, optimized, and potentially reversed – expanding the boundaries of the human lifespan. This paradigm shift represents a transition from reactive to proactive aging management, addressing fundamental age-related decline rather than downstream effects alone.
Today, there are over 90 FDA-approved peptide therapeutics with over 150 in clinical development and up to 600 undergoing preclinical trials. In medical practices across the globe, peptide therapies are being used to help treat cancer, infectious diseases, metabolic disorders, injuries, and much more.
Research continues to unveil the power of peptide therapies for disease management, performance optimization, and longevity strategies.
January 22, 2024
The global mental health crisis continues escalating at an alarming pace. Depression and anxiety alone currently cost the world economy $1 trillion annually. Experts project this economic burden could swell to a staggering $6-16 trillion by 2030 as rates of mental illness proliferate across the globe.
In the United States, mental health conditions already rank among the most prevalent, affecting over 57 million adults and approximately 26 million youth at some point in their lives. The state of mental health both in the US and worldwide persists on a downward trajectory, with 90% of US adults affirming the nation faces a mental health emergency. The personal, social, and economic repercussions across all sectors will quickly become catastrophic if current trends persist.
Despite the pressing need, presently available mainstream treatments often have poor long-term outcomes and fail to deliver sufficient relief — especially for millions suffering from severe, chronic conditions like treatment-resistant depression, complex PTSD, and addiction.
However, an emerging renaissance in psychedelic-assisted therapy research shows immense promise for transforming outcomes where conventional protocols fall short.
January 14, 2024
Settling into the new year is the perfect time to focus on renewal, renewing our commitment to delivering excellent care and patient outcomes, and leveraging every beneficial tool at our disposal. What better way to kick off 2024 than by highlighting key learnings around longevity, healthy aging, and improving our healthspans presented at 2023’s biggest anti-aging medicine event.
Throughout the four days of LongevityFest 2023, more than 120 acclaimed experts delivered upwards of 200 forward-thinking, thought-provoking, and, beyond all, practically relevant educational sessions.
The agenda was an unforgettable learning extravaganza for longevity science and anti-aging medicine enthusiasts. From delving into the exclusive insights of Blue Zone pioneer Dan Buettner to learning about insulin-like growth factor 1 and other vital components of healthy aging, thousands of dedicated health professionals in attendance were enriched with the latest knowledge and developments in the field.